Try
Protagonist Therapeutics Inc. Common Stock
PTGXUnited States
41 filed reports · 442 financial concepts · 0 earnings calls · 0 media appearances
Filed reports
41 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 3,945 | Jun 2016 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 3,350 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 273 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 167 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 25, 2026 | 660 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 6, 2025 | 169 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 109 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 6, 2025 | 110 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 21, 2025 | 321 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 7, 2024 | 125 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 6, 2024 | 120 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 7, 2024 | 104 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 27, 2024 | 324 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 2, 2023 | 105 | Open |
Financial data
442 concepts · 7,295 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial432 concepts · 7,190 facts · Aug 2014 to Jul 2026
- Money market funds72 · Dec 2018 to Jun 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Operating income loss58 · Dec 2014 to Jun 2026
- Allocated share based compensation expense57 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- General and administrative expense (US GAAP)57 · Dec 2014 to Jun 2026
- Operating expenses (US GAAP)57 · Dec 2014 to Jun 2026
- Research and development expense57 · Dec 2014 to Jun 2026
- Increase decrease in other accounts payable and accrued liabilities56 · Dec 2014 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets56 · Dec 2014 to Jun 2026
- Investment income interest56 · Dec 2014 to Jun 2026
- Payments to acquire property plant and equipment56 · Dec 2014 to Jun 2026
- Share based compensation56 · Dec 2014 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents55 · Dec 2014 to Jun 2026
- Stockholders equity (US GAAP)55 · Dec 2014 to Jun 2026
- Depreciation depletion and amortization54 · Dec 2014 to Jun 2026
- Accounts payable current53 · Dec 2015 to Jun 2026
- Accretion amortization of discounts and premiums investments53 · Dec 2015 to Jun 2026
- Accrued employee benefits current53 · Dec 2015 to Jun 2026
- Accrued liabilities current53 · Dec 2015 to Jun 2026
- Accumulated other comprehensive income loss net of tax53 · Dec 2015 to Jun 2026
- Additional paid in capital common stock53 · Dec 2015 to Jun 2026
- Assets53 · Dec 2015 to Jun 2026
Segment6 concepts · 81 facts · Dec 2022 to Jun 2026
- Allocated share based compensation expense14 · Dec 2022 to Jun 2026
- Investment income interest14 · Dec 2022 to Jun 2026
- Operating segment14 · Dec 2022 to Jun 2026
- Revenue14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Income tax expense benefit11 · Mar 2024 to Jun 2026
Product3 concepts · 14 facts · Mar 2018 to Jun 2023
- Janssen11 · Dec 2019 to Jun 2023
- Revenue2 · Mar 2018 to Jun 2018
- Contract with customer liability cumulative catch up adjustment to revenue change in estimate of transaction price1 · Mar 2018
Geography1 concepts · 10 facts · Dec 2015 to Dec 2025
- Property, Plant & Equipment, Net10 · Dec 2015 to Dec 2025
Segments
105 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 81 facts
- Single Reportable81 · Dec 2022 to Jun 2026
Product or servicesrt:ProductOrServiceAxis4 members · 12 facts
- Second Generation Analog Phase3 Cd Clinical Trial Primary Clinical Endpoint4 · Dec 2019 to Mar 2021
- License And Collaborative Revenue3 · Mar 2018 to Dec 2020
- Second Generation Analog Phase2 Cd Clinical Trial Primary Clinical Endpoint3 · Mar 2020 to Mar 2021
- License And Service2 · Mar 2023 to Jun 2023
Statement geographical1 member · 10 facts
- Au10 · Dec 2015 to Dec 2025
Product or serviceus-gaap:ProductOrServiceAxis1 member · 2 facts
- License And Collaborative Revenue2 · Mar 2018 to Jun 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary92 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary157 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes17 claims from 1 reports · Dec 2025
- Risk factors110 risks from 2 annual reports · 2024 to 2025
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.